Latest Capital Raises News

Chimeric Therapeutics reports encouraging clinical progress in its CAR-T and NK cell therapy trials, alongside FDA orphan drug designation and a strategic funding boost to propel development.

Patriot Resources has secured a binding agreement to acquire the high-grade Tassa Silver-Gold deposit in Peru and completed an oversubscribed $4.25 million capital raising to fund exploration and acquisitions across its portfolio.

Regener8 Resources has completed its first phase of Ultrafine™ soil sampling at the North Achilles project in NSW, revealing promising precious and base metal anomalies along major fault zones. The company is planning further sampling and geophysical surveys to advance towards drilling.

Yojee Limited reports a robust cash reserve and significant progress in its MOSAIC platform beta testing, alongside new customer contracts and strategic leadership hires, setting the stage for its 2026 commercial rollout.

Volt Resources has made significant strides in its US graphite refinery project and secured major funding for its Bunyu Graphite Mine in Tanzania, positioning itself strongly in the critical minerals sector.

GreenX Metals has raised A$13.6 million through a share placement to fund exploration at its Tannenberg Copper Project in Germany and Eleonore North Gold and Antimony Project in Greenland, reinforcing its balance sheet for 2026.

5E Advanced Materials has filed a Form S-1 registration with the SEC to raise up to $30 million through a common stock offering, aiming to advance its Fort Cady boron and lithium project. The capital raise is critical as the company navigates development milestones and financial challenges.

Emyria Limited has reported strong quarterly revenue growth driven by the expansion of its Empax clinic network across multiple Australian states, supported by a recent $8 million institutional placement to fund its national rollout and workforce expansion.

Alliance Nickel reported a $769,000 placement and a $422,000 R&D tax refund while progressing its NiWest Nickel-Cobalt Project, despite renegotiating its Stellantis offtake agreement due to market shifts.

Radiopharm Theranostics has reported promising interim results from its Phase 2b trial of RAD 101, showing high concordance with MRI in brain metastases patients, while progressing multiple other clinical programs and securing a strong cash position to fund operations into 2027.

AUB Group has successfully raised AUD 400 million through an institutional placement to fund its acquisition of Prestige and support future growth. A complementary AUD 40 million Share Purchase Plan will also be offered to eligible shareholders.

Vection Technologies has reported a remarkable quarter with a 250% jump in customer cash receipts and a landmark $7.8 million Defence order, signalling a new phase of growth and operational strength.